Full-Time

Senior Specialist

Quality Assurance Label Control

Posted on 4/16/2025

Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Senior

Company Historically Provides H1B Sponsorship

Summit, NJ, USA

Onsite Day Shift, Wednesday - Saturday, 6:30 a.m. - 4:30 p.m.

Category
QA & Testing
Quality Assurance
Required Skills
Excel/Numbers/Sheets
Requirements
  • B.S. Degree required.
  • Minimum of 5 years of GMP experience required.
  • 4 years of Quality Assurance experience required.
  • 3 years of labeling and label printer experience required.
  • Advanced computer skills (Excel and metrics).
Responsibilities
  • Supports all activities for the Quality Assurance Label Control group.
  • Responsible for issuing clinical and commercial in-process and final product labels for labeling operations.
  • Responsible for ensuring accurate printed information on labels in compliance with health authority requirements.
  • Coordinates with production teams to ensure timely issuance of labels.
  • Performs training of label control and issuance requirements for internal personnel as needed.
  • Ensures standard operating procedures (SOPs) related to job responsibilities define the steps necessary to complete tasks, etc. Writes, reviews and updates SOPs as required.
  • Carries out plans and actions to support new drug product launches, new market and other quality management activities as assigned.
  • Provides support during internal and health authority inspections and audits of facility.
  • Knowledge of quality processes, including label control and issuance, change control, product complaints, deviations, investigations and CAPA management.
  • Performs supplemental investigations/projects as required by Management.
  • Maintains knowledge of current GMPs and regulatory guidelines.
Desired Qualifications
  • EBR experience.
  • Zebra printer experience.
  • Leadership experience.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates BMS's R&D, improving drug development efficiency.
  • BMS's acquisition of 2seventy bio enhances its cancer cell therapy capabilities.
  • Positive Phase 3 trial results for Sotyktu boost BMS's psoriatic arthritis treatment portfolio.

What critics are saying

  • Increased competition in oncology may impact BMS's market share.
  • Layoffs could decrease employee morale, affecting operational efficiency.
  • Integration challenges from acquiring 2seventy bio may pose financial risks.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases, setting it apart in biopharma.
  • The company integrates AI in early lung cancer diagnosis, enhancing precision care.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

European HHHM
Apr 16th, 2025
Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care.

CMMB
Mar 24th, 2025
Our Values, Your Impact

In partnership with Bristol Myers Squibb, Catholic Medical Mission Board Inc. is playing a role in building the infrastructure and workforce to bring quality cancer care to rural Kenya.

PR Newswire
Mar 20th, 2025
Bristol Myers Squibb Appoints Osama Braiwish As General Manager For Saudi Arabia Gulf Countries

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan

Investors Hangout
Mar 20th, 2025
Bristol Myers Squibb Welcomes New Leadership in Gulf Region

Bristol Myers Squibb, a leader in the global biopharmaceutical sector, has appointed Osama Braiwish as its General Manager for the Gulf region, thereby enhancing its capacity to serve medical needs across various specialties.

Business Wire
Mar 12th, 2025
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all

INACTIVE